{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:09:08Z","timestamp":1792638548920,"version":"4.5.0"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002949","name":"Government of Jiangsu Province","doi-asserted-by":"publisher","award":["LGY2019006"],"award-info":[{"award-number":["LGY2019006"]}],"id":[{"id":"10.13039\/501100002949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.lungcan.2025.108593","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T11:52:13Z","timestamp":1748260333000},"page":"108593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors"],"prefix":"10.1016","volume":"205","author":[{"given":"Yuwen","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hehui","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanyong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongping","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shencun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2025.108593_b0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.lungcan.2018.08.017","article-title":"Prospective study revealed prognostic significance of responses in leptomeningeal metastasis and clinical value of cerebrospinal fluid-based liquid biopsy","volume":"125","author":"Xu","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108593_b0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1158\/1078-0432.CCR-22-1585","article-title":"Leptomeningeal metastasis from non\u2013small cell lung cancer and current landscape of treatments","volume":"29","author":"Ozcan","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108593_b0015","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/j.jtho.2016.06.029","article-title":"Leptomeningeal metastases in patients with NSCLC with EGFR mutations","volume":"11","author":"Li","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108593_b0020","first-page":"1","article-title":"Multidisciplinary management of patients with non\u2013small cell lung cancer with leptomeningeal metastasis in the tyrosine kinase inhibitor era","author":"Chen","year":"2022","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.lungcan.2025.108593_b0025","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1097\/JTO.0b013e3182773f21","article-title":"Leptomeningeal carcinomatosis in non\u2013small-cell lung cancer patients: impact on survival and correlated prognostic factors","volume":"8","author":"Lee","year":"2013","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108593_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101637","article-title":"Osimertinib Improves overall survival of EGFR-mutant NSCLC patients with leptomeningeal metastases","volume":"31","author":"Ye","year":"2023","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.lungcan.2025.108593_b0035","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.jtho.2019.12.113","article-title":"Osimertinib for patients with leptomeningeal metastases associated with EGFR T790M-positive advanced NSCLC: the AURA leptomeningeal metastases analysis","volume":"15","author":"Ahn","year":"2020","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2025.108593_b0040","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1200\/JCO.19.00457","article-title":"Osimertinib in patients with epidermal growth factor receptor mutation-positive non-small-cell lung cancer and leptomeningeal metastases: the BLOOM study","volume":"38","author":"Yang","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2025.108593_b0045","article-title":"EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with leptomeningeal metastasis from solid tumours","volume":"28","author":"Le Rhun","year":"2017","journal-title":"Ann. Oncol. off. J. Eur. Soc. Med. Oncol."},{"key":"10.1016\/j.lungcan.2025.108593_b0050","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/neuonc\/noz024","article-title":"The RANO Leptomeningeal Metastasis Group proposal to assess response to treatment: lack of feasibility and clinical utility and a revised proposal","volume":"21","author":"Le Rhun","year":"2019","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.lungcan.2025.108593_b0055","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-17-1582","article-title":"Cell-Cycle and DNA-damage response pathway is involved in leptomeningeal metastasis of non-small cell lung cancer","volume":"24","author":"Yun","year":"2018","journal-title":"Clin. Cancer Res. off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108593_b0060","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s11060-023-04520-2","article-title":"Cerebrospinal fluid circulating tumor DNA contributes to the detection and characterization of leptomeningeal metastasis in non-small cell lung cancer","volume":"165","author":"Miao","year":"2023","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.lungcan.2025.108593_b0065","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1002\/cam4.2156","article-title":"The clinical characteristic and prognostic factors of leptomeningeal metastasis in patients with non\u2010small\u2010cell lung cancer\u2010a retrospective study from one single cancer institute","volume":"8","author":"Yan","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.lungcan.2025.108593_b0070","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s11060-013-1228-x","article-title":"Leptomeningeal metastasis from solid tumors: a single center experience in Chinese patients","volume":"115","author":"Du","year":"2013","journal-title":"J. Neurooncol"},{"key":"10.1016\/j.lungcan.2025.108593_b0075","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamaoncol.2020.6758","volume":"7","author":"Akamatsu","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2025.108593_b0080","article-title":"Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC Harboring EGFR mutations: WJOG9717L study","volume":"17","author":"Kenmotsu","year":"2022","journal-title":"J. Thorac. Oncol. off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108593_b0085","doi-asserted-by":"crossref","DOI":"10.1111\/1759-7714.14880","article-title":"Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations","volume":"14","author":"Zhang","year":"2023","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.lungcan.2025.108593_b0090","doi-asserted-by":"crossref","DOI":"10.21037\/tlcr-20-984","article-title":"Osimertinib in combination with bevacizumab in EGFR-Mutated NSCLC with leptomeningeal metastases","volume":"9","author":"Jiang","year":"2020","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.lungcan.2025.108593_b0095","article-title":"Case report: Almonertinib in combination with bevacizumab for leptomeningeal metastases from epidermal growth factor receptor-mutation non-small cell lung cancer: Case series","volume":"12","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2025.108593_b0100","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1097\/CM9.0000000000002468","article-title":"Front-line therapy for brain metastases and non-brain metastases in advanced epidermal growth factor receptor-mutated non-small cell lung cancer: a network meta-analysis","volume":"136","author":"Zhu","year":"2023","journal-title":"Chin. Med. J. (Engl.)"},{"key":"10.1016\/j.lungcan.2025.108593_b0105","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1186\/s12967-022-03331-9","article-title":"Potential benefit of osimertinib plus bevacizumab in leptomeningeal metastasis with EGFR mutant non-small-cell lung cancer","volume":"20","author":"Yi","year":"2022","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.lungcan.2025.108593_b0110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.cllc.2023.11.010","article-title":"Advances in the diagnosis and treatment of advanced non-small-cell lung cancer with EGFR Exon 20 insertion mutation","volume":"25","author":"Liu","year":"2024","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108593_b0115","article-title":"Safety, clinical activity, and pharmacokinetics of Alflutinib (AST2818) in patients with advanced NSCLC With EGFR T790M mutation","volume":"15","author":"Shi","year":"2020","journal-title":"J. Thorac. Oncol. off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108593_b0120","article-title":"Efficacy and safety of re-challenging 160mg furmonertinib for advanced NSCLC after resistance to third-generation EGFR-TKIs targeted agents: a real-world study","volume":"184","author":"Qi","year":"2023","journal-title":"Lung Cancer Amst. Neth."},{"key":"10.1016\/j.lungcan.2025.108593_b0125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s12885-023-10676-x","article-title":"Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM\/LM as salvage therapy","volume":"23","author":"Xu","year":"2023","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2025.108593_b0130","first-page":"768","article-title":"Successful salvage therapy using high-dose furmonertinib (AST2818) for non-small-cell lung cancer after Osimertinib resistance: a case report, Anticancer","volume":"33","author":"Cheng","year":"2022","journal-title":"Drugs"},{"issue":"17","key":"10.1016\/j.lungcan.2025.108593_b0135","first-page":"1034","article-title":"Efficacy and influencing factors on intrathecal chemotherapy with pemetrexed via the Ommaya reservoir for leptomeningeal carcinomatosis from non-small cell lung cancer","volume":"30","author":"Xie","year":"2023","journal-title":"Chin. J. Cancer Prev. Treat."},{"key":"10.1016\/j.lungcan.2025.108593_b0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102384","article-title":"Efficacy and safety of intrathecal pemetrexed for TKI-failed leptomeningeal metastases from EGFR+ NSCLC: an expanded,single-arm, phase II clinical trial","volume":"9","author":"Fan","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.lungcan.2025.108593_b0145","article-title":"Concurrent TP53 mutations facilitate resistance evolution in EGFR-Mutant lung adenocarcinoma","volume":"17","author":"Vokes","year":"2022","journal-title":"J. Thorac. Oncol. Off. Publ. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.lungcan.2025.108593_b0150","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1913662","article-title":"Overall Survival with Osimertinib in untreated, EGFR-mutated advanced NSCLC","volume":"382","author":"Ramalingam","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108593_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.723562","article-title":"Survival outcomes of patients with epidermal growth factor receptor mutations in non-small cell lung cancer with leptomeningeal metastasis","volume":"11","author":"Li","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2025.108593_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.jns.2020.116706","article-title":"Leptomeningeal metastasis from solid tumors","volume":"411","author":"Thakkar","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.lungcan.2025.108593_b0165","article-title":"Survival following Ommaya reservoir placement for neoplastic meningitis","volume":"22","author":"Roguski","year":"2015","journal-title":"J. Clin. Neurosci. off. J. Neurosurg. Soc. Australas."},{"key":"10.1016\/j.lungcan.2025.108593_b0170","article-title":"Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections","volume":"293","author":"Wr","year":"1975","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2025.108593_b0175","article-title":"Clinical Safety and Efficiency of the H-Port for Treatment of Leptomeningeal Metastasis","volume":"67","author":"Sm","year":"2024","journal-title":"J. Korean Neurosurg. Soc."},{"key":"10.1016\/j.lungcan.2025.108593_b0180","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-024-04653-9","article-title":"Ommaya reservoir use in pediatric ALL and NHL: a review at St. Jude Children\u2019s Research Hospital","volume":"93","author":"Gaietto","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.lungcan.2025.108593_b0185","doi-asserted-by":"crossref","first-page":"509","DOI":"10.3389\/fonc.2018.00509","article-title":"The comparative treatment of intraventricular chemotherapy by ommaya reservoir vs. lumbar puncture in patients with leptomeningeal carcinomatosis","volume":"8","author":"Delgado","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2025.108593_b0190","article-title":"Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer","author":"Gwak","year":"2013","journal-title":"J. Thorac. Oncol. off. Publ. Int. Assoc. Study Lung Cancer 8"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500225004854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T14:50:48Z","timestamp":1752591048000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500225004854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":38,"alternative-id":["S0169500225004854"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108593","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic profiling and prognostic factors of leptomeningeal metastasis in EGFR-mutant NSCLC after resistant to third-generation EGFR-tyrosine kinase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2025.108593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108593"}}